Biopharmaceutical company, BioXcel Therapeutics, Inc. (Nasdaq: BTAI), has been granted FDA Fast Track designation for BXCL701 in combination with a CPI for the treatment of…
February 13, 2024
February 12, 2024
FDA Clearance for T2 Biosystems Diagnostic Panel
T2 Biosystems, Inc. (Nasdaq: TTOO) has received 510(k) clearance from the FDA for its expanded T2Bacteria® Panel, adding the capability to detect another bacterial species,…
February 06, 2024
Alto Neuroscience Soars following Upsized IPO
Precision medicine company, Alto Neuroscience (NYSE: ANRO), began its first day of trading on Thursday last week with a mixed response from the market. Alto…
Vertex Pharmaceuticals (Nasdaq: VRTX) is offering hope to the 80 million Americans suffering with acute pain each year with a non-addictive pain management alternative. Today,…
Australian pharmaceutical company, Incannex Healthcare Inc. (Nasdaq: IXHL), has received independent Institutional Review Board (IRB) approval for a Phase 2/3 clinical trial to assess the…
January 10, 2024
Clearmind Medicine Meets with FDA to Discuss Clinical Trial in Alcohol Use Disorder; Shares Up 72%
Clearmind Medicine (Nasdaq: CMND) has completed a Type A meeting with the FDA to discuss the Company’s clinical trial of CMND-100 for the treatment of…
January 10, 2024
Hyperfine Launches AI-powered Brain Imaging Software
Medical device company, Hyperfine, Inc. (Nasdaq: HYPR) has announced the launch of the eighth generation of its AI-powered Swoop® system software. The latest software has…
Biopharmaceutical company, Ambrx (Nasdaq: AMAM), has announced it will be acquired by Johnson & Johnson for $28.00 per share in cash, for a total equity…
January 02, 2024
Better Therapeutics Targets FDA Breakthrough Device Designation for Liver Disease Treatment
Prescription digital therapeutics (PDTs) pioneer, Better Therapeutics (Nasdaq: BTTX), has submitted a request to the FDA for Breakthrough Device Designation for its novel PDT designed…
December 20, 2023
First Dosing in Clinical Trial to Trigger $10M Payment for Compugen; Share Price Skyrockets 170%
Cancer immunotherapy company, Compugen Ltd (Nasdaq: CGEN) will be eligible to receive a milestone payment of $10 million from AstraZeneca (Nasdaq: AZN) when the first…
BioStem Technologies (OTC: BSEM) has strengthened its Board of Directors this week with the appointment of industry veterans, Mr. Thomas Dugan as Chairman and Mr….
December 13, 2023
FDA Grants PMA Supplement Approval for ReShape Lifesciences Lap Band; Shares Surge 100%
ReShape Lifesciences (Nasdaq: RSLS) has been granted FDA approval of a PMA supplement for the company’s next generation, enhanced Lap-Band® 2.0 FLEX. The company’s share…